Chronická B-lymfocytární leukémie
| Title in English | Chronic B-lymphocytic leukemia |
|---|---|
| Authors | |
| Year of publication | 2011 |
| Type | Article in Periodical |
| Magazine / Source | Postgraduální medicína |
| MU Faculty or unit | |
| Citation | |
| Field | Oncology and hematology |
| Keywords | epidemiology; chemoimmunotherapy; chronic lymphocytic leukemia; prognostic factors |
| Description | Chronic lymphocytic leukemia (CLL) is a low-grade lymphoma, typically found in elderly people. CLL is the most common leukemia in the Western World, it makes up almost 30 % of all leukemias. Pathogenesis of CLL is still unknown, however, an antigen stimulation, apoptotic defects and the role of microenvironment are often discussed. At present, new prognostic factors are being analyzed in order to define a risk subgroup of patients that would benefit from early and intensive start of therapy. Treatment of CLL has made a great progress in the last decade. While a few years ago chlorambucil was a golden standard in the CLL therapy, currently, the combination of a chemotherapy backbone with the moantibody has opened up new horizons for CLL therapy. Patients treated with chemoimmunotherapy can achieve years of complete remission of CLL. Allogenic transplantation still represents the only curative approach. |